Kura Oncology (KURA)

This week, 6 Biotechnology stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

Hottest Manufacturing Stocks Now – WGO DVAX SCYX BMRA

By Portfolio Grader Oct 3, 2016

The following stocks were the biggest movers and shakers in the Manufacturing sector today.

Hottest Manufacturing Stocks Now – GURE ARDM OCRX KURA

By Portfolio Grader Sep 16, 2016

The following stocks were the biggest movers and shakers in the Manufacturing sector today.

Biggest Movers in Manufacturing Stocks Now – YECO KURA VTGN CNCE

By Portfolio Grader Aug 30, 2016

The Manufacturing sector saw plenty of trading activity today, including the following leaders and losers.

Biggest Movers in Manufacturing Stocks Now – CLVS REPH VHI CVO

By Portfolio Grader Aug 23, 2016

The following stocks were the biggest movers and shakers in the Manufacturing sector today.

Kura Oncology Inc: KURA Stock Delivers, But Don’t Trust It

By John Kilhefner, Senior Managing Editor, Lango Franchise Aug 11, 2016

Kura Oncology is seeing its biggest one-day gain yet, but that doesn't mean buy. Steer clear from the analysts on this one and look for a company with an actual product.

Kura Oncology files for $150M common stock offering, mixed securities shelf (NASDAQ:KURA)

From Seeking Alpha Nov 3, 2023

Kura Oncology files for $150M stock offering and mixed securities shelf in a recent prospectus, but it does not include an offer to sell or buy securities.

Kura Oncology GAAP EPS of -$0.50 beats by $0.05 (NASDAQ:KURA)

From Seeking Alpha Nov 2, 2023

Kura Oncology beats expectations with Q3 earnings as both research and development expenses and general and administrative expenses surpass previous year's...

BofA starts Syndax at buy, cites

From Seeking Alpha Oct 25, 2023

BofA Securities initiates coverage of Syndax (SNDX) at a buy, citing first mover advantage for its drug revumenib in the treatment of certain leukemias. Read more here.

BofA starts Kura at buy, cites revenue potential of lead drug ziftomenib (NASDAQ:KURA)

From Seeking Alpha Aug 11, 2023

BofA has initiated coverage of Kura Oncology (KURA) with a buy rating, commenting that it sees the stock as undervalued given the long-term revenue potential of its lead drug.

Kura Oncology GAAP EPS of -$0.53 beats by $0.01 (NASDAQ:KURA)

From Seeking Alpha Aug 3, 2023

Kura Oncology press release (KURA): Q2 GAAP EPS of -$0.53 beats by $0.01.$477 million in cash, equivalents and investments provide runway to mid-2026

Analysts Are Bullish on These Healthcare Stocks: Urogen Pharma (URGN), Kura Oncology (KURA)

From TipRanks Dec 12, 2022

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Urogen Pharma (URGN – Research Report), Kura Oncolog...

Kura Oncology (KURA)

3 Under-the-Radar Stocks That AI Predicts Will Soar in May

7 Undiscovered Stocks to Watch for the Next Big Thing

7 Cheap Biotech Stocks to Buy Now

New FDA Approval Could Send Merck Higher

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Kura Oncology (KURA)

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

KURA Stock Predictions, Articles, and Kura Oncology News

Subscriber Sign in